Some Chinese cities pause car-buying subsidies as funds run out
Notices from governments in Zhengzhou and Luoyang blamed the subsidy pause on the first round of funding allocated by Beijing for the programme running out, while Shenyang and Chongqing said the suspension was due to adjustments to improve capital efficiency.
The northwestern region of Xinjiang issued a similar suspension.
China's government has leaned on subsidies for big-ticket items, including cars, home appliances and some electronics to get people spending as consumer sentiment in the country remains sluggish amid a prolonged property slump and concerns over wage growth and unemployment.
The programmes have been embraced with some enthusiasm. As of May 31, there were more than 4 million applications submitted this year for car-specific trade-in subsidies, according to the country's Ministry of Commerce.
Chinese retail sales data for May released earlier this week surprised on the upside with subsidies cited as one reason for the higher-than-expected 6.4% growth.
While there has been no official announcement about when more funds from the central government will be released for programmes, China's National Development and Reform Commission and Ministry of Finance have said the subsidies would continue throughout 2025, leading analysts to expect new funds for the third quarter to be made available from July.
The subsidy programme has also met with controversy, however, particularly in the auto sector. China's auto industry, the world's largest, has attracted criticism from regulators over a deepening price war that has sapped the sector's profitability.
Official media in China's Henan province, where Zhengzhou is the capital, last week reported, citing unnamed sources, that China's central government had taken note of some loopholes in the subsidy schemes and would look to make adjustments.
One of the major issues identified by Chinese media and regulators is so-called 'zero-mileage used cars', which refers to the practice of selling brand new cars as heavily discounted second-hand vehicles to get rid of inventory.
The report in Henan government-owned newspaper Dahe Daily added that sales of 'zero-mileage used cars' were one of the key factors leading to subsidies being used up ahead of expectations, necessitating the suspensions.
Some businesses were disguising new or nearly new cars as used cars that they could trade in to obtain the subsidies, the newspaper said.
The People's Daily, a national newspaper that often signals the positions of China's top leaders on a variety of issues, also called for a crackdown on the zero-mileage used cars, weeks after Great Wall Motor's (601633.SS), opens new tab Chairman Wei Jianjun publicly condemned the practice.
China's industry ministry in early June summoned automakers to a meeting where it called for the sector to halt its price wars, Reuters reported last week.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
2 hours ago
- Reuters
China's Innogen expects to complete weight-loss drug trials next year
SHANGHAI, July 1 (Reuters) - Chinese drugmaker Innogen expects to complete a late-stage clinical trial of its experimental weight-loss drug candidate next year, its CEO said on Tuesday, the latest Chinese company to join the race to develop obesity treatments. Chinese companies are rushing to develop drugs belonging to the GLP-1 class of medications for weight loss and related conditions as the patent of Novo Nordisk's ( opens new tab semaglutide, a key active ingredient in its best-selling Ozempic and Wegovy drugs, is due to end in early 2026 in China. "I think the Phase IIB will be out by the end of this year, then Phase III will be (finished) by next year,' Innogen CEO Wang Qinghua told Reuters in an interview about the company's experimental drug candidate. Initial results from an early trial, published in June, opens new tab, showed people on the experimental efsubaglutide alfa injection lost about 7% of their body weight after four weeks. By comparison, large-scale trials over a longer period for Novo's weight-loss drug Wegovy helped people lose an average 15% of their body weight, according to its clinical trial data. Wang said the efficacy in Innogen's experimental injection was not fully visible in the firm's drug study because of the short evaluation time, adding the company expects to get more significant weight reduction as it continues with more studies. Chinese regulators have already approved the Shanghai-based company's self-developed efsubaglutide alfa as a once-weekly injection for the control of Type 2 diabetes in January. Yurou Zheng, an analyst at Morningstar, said the near-term challenge for weight-loss drugs in China would be potential price competition, as more drugs are coming online. "I think many users are more likely to pivot to cheaper options if the efficacy profiles are similar or even slightly less superior as long as they are well within a few percentage points," he said in a note. On Friday, Chinese drugmaker Innovent Biologics ( opens new tab became the latest local company entering the increasingly crowded weight-loss drug market, saying its treatment mazdutide, which is licensed from Eli Lilly (LLY.N), opens new tab, was approved by the country's regulators. The Suzhou-based firm said in June that a Phase III trial showed that after 24 weeks of treatment, 6 mg of mazdutide led to about an 8% change in body weight from baseline. Underscoring growing competitive pressure in China, India's Biocon ( opens new tab dropped plans to commercialise its weight loss drugs in China, a senior executive told Reuters last week.
Daily Mail
3 hours ago
- Daily Mail
China's biggest coffee chain opens first US locations
A Starbucks competitor has opened its first location in the US. Luckin Coffee, known for its no-frills menu and ultra-low prices, has already given Starbucks a run for its money in its home country of China. It has now opened its first two American shops this week — both near the campus of New York University. The Big Apple's newest coffee shop opened on Monday. The chain celebrated Monday's opening with free tote bags with for the first 100 guests and $.99 drinks for early customers. In China, the no-frills coffee chain has consistently pulled in young shoppers, with aggressive TikTok campaigns and low prices. Luckin's strategy is clear: keep it simple and cheap. In China, the brand has leaned into aggressive TikTok marketing and a grab-and-go model that caters to students and professionals on the run. The chain has a history of undercutting Starbuck's value. A standard cup of Starbucks coffee will typically cost New Yorkers around $6 to $7. In China, Starbucks drinks are typically 30 percent more expensive than Luckin's. Luckin has used its simple, easily-scaled restaurants with bargain basement prices to become one of China's biggest restaurant chains. By 2019, the brand had overtaken Starbucks as the largest coffee chain in China. It currently operates 22,000 stores in the country, triple the size of the Seattle-based brewer's Chinese locations. Meanwhile, Starbucks' forray into the Chinese market is appearing to lose steam. The company is fighting off rumors that it was exploring a sale of all its Chinese store locations. The New York openings also come as Starbucks attempts to mount a sales resurgence back in the US. Last year, Starbucks posted declining growth , prompting a wave of changes in the company's restaurants and in the C-suite. The coffee chain slashed products from its menus , changed its perks programs , and pilfered Chipotle's CEO to become the coffee chain's top boss. 'People love Starbucks, but I've heard from some customers that we've drifted from our core,' Brian Niccol, the new CEO, said during a 2024 earnings call. 'As a result, some are visiting less often, and I think today's results tell that same story.' In April, the company reported a two percent increase in net sales. But Niccol said the company is still facing headwinds from higher costs and decreasing consumer strength. Meanwhile, Starbucks might not be the only coffee chain in the Chinese coffee-makers sights.
Reuters
5 hours ago
- Reuters
HSBC raises average gold price forecasts for 2025 and 2026
July 1 (Reuters) - HSBC raised its 2025 average gold price forecast to $3,215 an ounce from $3,015 and its 2026 forecast to $3,125 from $2,915, citing elevated risks and government debt. Gold tends to perform well during periods of economic uncertainty and geopolitical tension, which lifted spot gold to a record high of $3,500.05 an ounce in late April. Spot gold was trading at $3,348.50/oz at 1146 GMT on Tuesday. "We anticipate a wide and volatile trading range of $3,600-3,100/oz for the rest of the year and year-end prices of $3,175/oz for 2025 and $3,025/oz for 2026," the bank said in a note on Tuesday. U.S. Senate Republicans on Monday evening were still trying to pass President Donald Trump's sweeping tax cut and spending bill despite divisions within the party about its expected $3.3 trillion hit to the nation's debt pile. Meanwhile, Treasury Secretary Scott Bessent warned that countries could be notified of sharply higher tariffs as a July 9 deadline approaches. HSBC said that even if gold prices ease, levels above $3,000 an ounce have reinforced gold's role as a safe haven and effective portfolio diversifier. It noted that central bank gold purchases will moderate on further rallies above $3,300 and could increase should gold correct nearer to $3,000. On the physical front, the bank said further gold price gains above $3,500 could lead to reduced demand in the jewellery, coin and small bar markets, particularly in economies such as India and China.
